evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,805 questions · 2,912 findings · 307 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 706 · 24.2%GRADE not reported 133 · 4.6%Very low 786 · 27%Low 696 · 23.9%Moderate 474 · 16.3%High 117 · 4%

Intervention not reported

Participant‐rated global assessment of treatment success · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative treatments

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Adverse events (total): · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative treatments

It is very uncertain whether the intervention changes adverse events (total): (very low certainty).

1 finding from 1 review

Intervention not reported

Adverse events (serious ‐ resulting in hospitalisation or death) · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative treatments
1 finding from 1 review

Intervention not reported

Revision, re‐operation, or treatment failure · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative treatments

It is very uncertain whether the intervention changes revision, re‐operation, or treatment failure (very low certainty).

1 finding from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Cardiovascular mortality · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)

Usual care with ivabradine showed no clear difference in mortality from cardiovascular causes ( compared with placebo, usual care, or no treatment (moderate certainty).

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Time to first hospitalisation for heart failure during · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Number of days spent in hospital due to heart failure during · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Rate of serious adverse events · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Exercise capacity · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Costs · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Quality of life · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Time to first hospitalisation for heart failure during · patients with chronic heart failure with preserved ejection fraction

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Number of days spent in hospital due to heart failure during · patients with chronic heart failure with preserved ejection fraction

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Rate of serious adverse events · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Quality of life · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Exercise capacity · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review